Sarepta Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1996
Net Income	16.9	-535.98	-703.49	-418.78	-554.13	-715.08	Upgrade
Depreciation & Amortization	57.07	58.89	54.6	49.34	39.74	30.55	Upgrade
Share-Based Compensation	181.96	182.51	233.02	113.94	108.07	78.6	Upgrade
Other Operating Activities	-789.59	-206.42	90.53	-187.68	513.79	149.46	Upgrade
Operating Cash Flow	-533.67	-500.99	-325.35	-443.17	107.47	-456.46	Upgrade
Capital Expenditures	-99.07	-76.11	-30.82	-38.49	-82.2	-59.63	Upgrade
Acquisitions	98	98	-1	100.2	108.07	-172.56	Upgrade
Change in Investments	62.71	-176.46	-1,013.63	436.01	-144.09	521.99	Upgrade
Other Investing Activities	-21.15	-11.24	-1.43	-2.31	-3.5	-3.08	Upgrade
Investing Cash Flow	40.5	-165.8	-1,046.88	495.41	-121.72	286.73	Upgrade
Share Issuance / Repurchase	45.35	51.25	30.04	569.33	396.01	401.96	Upgrade
Debt Issued / Paid	0	0	303.45	0	291.11	244.94	Upgrade
Other Financing Activities	-	73.76	-100.99	-7.77	-4.8	-4.34	Upgrade
Financing Cash Flow	45.35	125	232.51	561.57	682.32	642.55	Upgrade
Net Cash Flow	-447.82	-541.79	-1,139.72	613.81	668.07	472.82	Upgrade
Free Cash Flow	-632.74	-577.1	-356.17	-481.66	25.26	-516.09	Upgrade
Free Cash Flow Margin	-45.09%	-46.42%	-38.17%	-68.62%	4.68%	-135.52%	Upgrade
Free Cash Flow Per Share	-6.73	-6.25	-4.07	-5.93	0.32	-7.01	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).